

REMARKS

Remarks on Amendments to the Specification

The preliminary amendments to the specification of the instant application have their basis in U.S. Application Serial Nos. 08/864,357, 09/087,210 and 09/120,264 all of which were incorporated by reference into U.S. Application Serial No. 09/949,926.

The paragraph amended at page 3 lines 9-15 adds a reference to Figure 21 which is referred to in U.S. Application Serial Nos. 08/864,357 at page 4 as Fig. 1, 09/087,210 at page 4 as Fig. 1, and 09/120,264 at page 4 as Fig. 1.

The paragraphs added at page 12 line 16 describe Figures 21, 22A, 22B, and 22C. Figures 21, 22A, 22B, and 22C are described in U.S. Application Serial No. 08/864,357 at page 12. Figure 21 is described in U.S. Application Serial No. 09/087,210 at pages 8-9 as Fig. 1, and in U.S. Application Serial No. 09/120,264 at page 9 as Fig. 1.

The paragraphs added at page 21 line 15 are found in U.S. Application Serial No. 08/864,357 at pages 18-29. Applicants respectfully note that Amendments to the specification within pages 18-29 of 08/864,357 were entered during the prosecution of U.S. Application Serial No. 08/864,357 and that the paragraphs added at page 21 line 15 include these amendments. For expediency, Applicants incorporate the applicable amendments entered during prosecution of U.S. Application Serial No. 08/864,357 into the present application. Attached, for Examiner's benefit, is a copy of the Amendment to the Specification from the 08/864,357 prosecution.

For the foregoing reasons, Applicants respectfully submit that there is no new matter in the instant application.

Additionally, Applicants submit a sequence listing for the sequences present in this preliminary amendment.

Remarks on Amendments to the Drawings

Figures 21, 22A, 22B, and 22C correspond to Figures 1, 2A, 2B and 2C of U.S. Application Serial Nos. 08/864,357. Figure 21 also corresponds to Figure 1 of U.S. Application Serial Nos. 09/087,210 and 09/120,264. U.S. Application Serial Nos. 08/864,357, 09/087,210, and 09/120,264 were incorporated by reference into U.S. Application Serial No. 09/949,926. Hence, Applicants respectfully submit that there is no new matter in the instant application.

Remarks on Amendments to the Claims


Applicants have amended claims 1-10 and have added new claims 89-95. Applicants respectfully maintain that the term recombinant human uteroglobin as recited in the pending claims is adequately supported by the disclosures in the specification. No new matter has been introduced.

Applicants respectfully submit that recombinant human uteroglobin, as described in the specification and as claimed, is not the same protein as Diernyck's human CC16. Diernyck does not disclose any amino acid sequence for CC16.

Hence, Applicants respectfully submit that these claims are in condition for allowance and notice to that effect is respectfully requested.

Respectfully submitted

KRAMER LEVIN NAFTALIS & FRANKEL LLP
Attorneys for Applicants

By: 
Robert E. Alderson, Jr.
Reg. No. 44,500
Kramer Levin Naftalis & Frankel LLP
919 Third Avenue
New York, New York 10022
(212) 715-9100